Literature DB >> 22499677

α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.

Steven P Braithwaite1, Jeffry B Stock, M Maral Mouradian.   

Abstract

Phosphorylation is a key post-translational modification necessary for normal cellular signaling and, therefore, lies at the heart of cellular function. In neurodegenerative disorders, abnormal hyperphosphorylation of pathogenic proteins is a common phenomenon that contributes in important ways to the disease process. A prototypical protein that is hyperphosphorylated in the brain is α-synuclein (α-syn) - found in Lewy bodies and Lewy neurites - the pathological hallmarks of Parkinson's disease (PD) and other α-synucleinopathies. The genetic linkage of α-syn to PD as well as its pathological association in both genetic and sporadic cases have made it the primary protein of interest. In understanding how α-syn dysfunction occurs, increasing focus is being placed on its abnormal aggregation and the contribution of phosphorylation to this process. Studies of both the kinases and phosphatases that regulate α-syn phosphorylation are beginning to reveal the roles of this post-translational modification in disease pathogenesis. Modulation of α-syn phosphorylation may ultimately prove to be a viable strategy for disease-modifying therapeutic interventions. In this review, we explore mechanisms related to α-syn phosphorylation, its biophysical and functional consequences, and its role in neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22499677     DOI: 10.1515/revneuro-2011-0067

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  16 in total

1.  Chemical synthesis of proteins using peptide hydrazides as thioester surrogates.

Authors:  Ji-Shen Zheng; Shan Tang; Yun-Kun Qi; Zhi-Peng Wang; Lei Liu
Journal:  Nat Protoc       Date:  2013-11-14       Impact factor: 13.491

Review 2.  Interactions between the Intrinsically Disordered Proteins β-Synuclein and α-Synuclein.

Authors:  Jonathan K Williams; Xue Yang; Jean Baum
Journal:  Proteomics       Date:  2018-09-09       Impact factor: 3.984

3.  Assembly of the SLIP1-SLBP complex on histone mRNA requires heterodimerization and sequential binding of SLBP followed by SLIP1.

Authors:  Nitin Bansal; Minyou Zhang; Aishwarya Bhaskar; Patrick Itotia; EunHee Lee; Lyudmila S Shlyakhtenko; TuKiet T Lam; Andrew Fritz; Ronald Berezney; Yuri L Lyubchenko; Walter F Stafford; Roopa Thapar
Journal:  Biochemistry       Date:  2013-01-11       Impact factor: 3.162

4.  Low-Intensity Ultrasound Decreases α-Synuclein Aggregation via Attenuation of Mitochondrial Reactive Oxygen Species in MPP(+)-Treated PC12 Cells.

Authors:  Mrigendra Bir Karmacharya; Binika Hada; So Ra Park; Byung Hyune Choi
Journal:  Mol Neurobiol       Date:  2016-10-06       Impact factor: 5.590

5.  Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.

Authors:  Hye-Jin Park; Kang-Woo Lee; Stephanie Oh; Run Yan; Jie Zhang; Thomas G Beach; Charles H Adler; Michael Voronkov; Steven P Braithwaite; Jeffry B Stock; M Maral Mouradian
Journal:  J Neuropathol Exp Neurol       Date:  2018-02-01       Impact factor: 3.685

6.  Pathological α-synuclein impairs adult-born granule cell development and functional integration in the olfactory bulb.

Authors:  Johanna Neuner; Saak V Ovsepian; Mario Dorostkar; Severin Filser; Aayush Gupta; Stylianos Michalakis; Martin Biel; Jochen Herms
Journal:  Nat Commun       Date:  2014-05-28       Impact factor: 14.919

7.  Impaired c-Fos and polo-like kinase 2 induction in the limbic system of fear-conditioned α-synuclein transgenic mice.

Authors:  Heinrich Schell; Cindy Boden; André Maia Chagas; Philipp J Kahle
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

8.  Pramipexole reduces phosphorylation of α-synuclein at serine-129.

Authors:  Kai-Yin Chau; J Mark Cooper; Anthony Henry V Schapira
Journal:  J Mol Neurosci       Date:  2013-05-18       Impact factor: 3.444

9.  Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation.

Authors:  B I Pérez-Revuelta; M M Hettich; A Ciociaro; C Rotermund; P J Kahle; S Krauss; D A Di Monte
Journal:  Cell Death Dis       Date:  2014-05-08       Impact factor: 8.469

10.  New α- and γ-synuclein immunopathological lesions in human brain.

Authors:  Irina Surgucheva; Kathy L Newell; Jeffrey Burns; Andrei Surguchov
Journal:  Acta Neuropathol Commun       Date:  2014-09-11       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.